US-based firm Veran Medical Technologies has released positive, cost-effective final results from the initial study of its SPiNPerc procedure.

Results from the SPiNPerc endobronchial percutaneous biopsy trial support the use of a percutaneous approach to biopsy when a traditional bronchoscopic method is not possible.

The company said that the trial showed hospital savings of $693,327 per 200 lung cancer screening patients with positive findings.

The Lung Cancer Management trial was written by thoracic surgeon and expert in the SPiNPerc procedure Dr Adam Lee, Dr Abhijit Raval and Leah Amir.

According to the practice points, having both navigation bronchoscopy and computed tomography fine-needle aspiration ready on the same platform allows an easy transition from one procedure to the other if the first approach fails.

Dr Adam Lee said: "Veran’s technology gives me every tool I need to diagnosis and treat my patient in the best way, which demonstrates the practice of good medicine."

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.
"Veran’s SPiNPerc technology gives me the option of an endobronchial and percutaneous approach to detect lung cancer."

Veran Medical Technologies marketing global vice president Rob Powers said: "ENB has been on the market for nearly ten years and the five-year survival rate remains an unacceptable 15%-16%.

"We are providing both an advanced ENB system and innovations like SPiNPerc that have the potential to impact survival.

"Setting up a comprehensive lung cancer screening program is important. The SPiNPerc procedure clearly offers a cost-effective new patient care pathway for those patients with a suspicious lesion found on their CT scan."

In addition to the SPiNPerc endobronchial percutaneous biopsy trial, a SPiNPerc clinical trial is being conducted at Johns Hopkins Hospital in Baltimore, Maryland.

Johns Hopkins Division of Pulmonary and Critical Care clinical chief Lonny Yarmus said: "Veran’s SPiNPerc technology gives me the option of an endobronchial and percutaneous approach to detect lung cancer. Many of my patients in the study previously would have needed additional visits to get an answer."

Image: Veran’s SPiNView system. Photo: courtesy of PRNewsWire/ Veran Medical Technologies.